FB-825 is under clinical development by Oneness Biotech and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FB-825’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FB-825 overview
FB-825 is under development for the treatment of allergic asthma, atopic dermatitis and hyperimmunoglobulin E syndrome. It is administered through intravenous and subcutaneous route. FB-825 is a humanized monoclonal antibody that targets to the specific CemX domain and kills the membrane IgE positive B lymphocytes. It is administered by intravenous route. It was under development for the treatment of food allergy and allergic rhinitis.
Oneness Biotech overview
Oneness Biotech is a biopharmaceutical company. The company’s product pipeline comprises ON101 against diabetic foot ulcers, FB825 for atopic dermatitis and allergic asthma, FB704A against severe asthma, OB318 against cancer and FB918 against asthma. It offers products in the therapeutic areas of dermatology, immunology and infectious diseases, among others. Oneness Biotech is headquartered in Taipei, Taiwan.
For a complete picture of FB-825’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
